S&P 500   3,776.79 (-0.37%)
DOW   30,241.48 (-0.25%)
QQQ   281.10 (-0.37%)
AAPL   145.88 (-0.15%)
MSFT   248.38 (-0.20%)
META   137.91 (-1.69%)
GOOGL   100.78 (-0.85%)
AMZN   120.44 (-0.54%)
TSLA   238.96 (-4.20%)
NVDA   131.29 (-0.29%)
NIO   15.91 (-4.90%)
BABA   84.13 (+0.02%)
AMD   67.64 (-0.38%)
T   15.91 (-1.12%)
MU   54.69 (+1.35%)
CGC   3.02 (-3.82%)
F   12.46 (+0.81%)
GE   67.59 (+0.07%)
DIS   100.11 (-1.31%)
AMC   7.39 (-5.62%)
PYPL   93.83 (+1.12%)
PFE   44.04 (-0.94%)
NFLX   233.71 (-2.92%)
S&P 500   3,776.79 (-0.37%)
DOW   30,241.48 (-0.25%)
QQQ   281.10 (-0.37%)
AAPL   145.88 (-0.15%)
MSFT   248.38 (-0.20%)
META   137.91 (-1.69%)
GOOGL   100.78 (-0.85%)
AMZN   120.44 (-0.54%)
TSLA   238.96 (-4.20%)
NVDA   131.29 (-0.29%)
NIO   15.91 (-4.90%)
BABA   84.13 (+0.02%)
AMD   67.64 (-0.38%)
T   15.91 (-1.12%)
MU   54.69 (+1.35%)
CGC   3.02 (-3.82%)
F   12.46 (+0.81%)
GE   67.59 (+0.07%)
DIS   100.11 (-1.31%)
AMC   7.39 (-5.62%)
PYPL   93.83 (+1.12%)
PFE   44.04 (-0.94%)
NFLX   233.71 (-2.92%)
S&P 500   3,776.79 (-0.37%)
DOW   30,241.48 (-0.25%)
QQQ   281.10 (-0.37%)
AAPL   145.88 (-0.15%)
MSFT   248.38 (-0.20%)
META   137.91 (-1.69%)
GOOGL   100.78 (-0.85%)
AMZN   120.44 (-0.54%)
TSLA   238.96 (-4.20%)
NVDA   131.29 (-0.29%)
NIO   15.91 (-4.90%)
BABA   84.13 (+0.02%)
AMD   67.64 (-0.38%)
T   15.91 (-1.12%)
MU   54.69 (+1.35%)
CGC   3.02 (-3.82%)
F   12.46 (+0.81%)
GE   67.59 (+0.07%)
DIS   100.11 (-1.31%)
AMC   7.39 (-5.62%)
PYPL   93.83 (+1.12%)
PFE   44.04 (-0.94%)
NFLX   233.71 (-2.92%)
S&P 500   3,776.79 (-0.37%)
DOW   30,241.48 (-0.25%)
QQQ   281.10 (-0.37%)
AAPL   145.88 (-0.15%)
MSFT   248.38 (-0.20%)
META   137.91 (-1.69%)
GOOGL   100.78 (-0.85%)
AMZN   120.44 (-0.54%)
TSLA   238.96 (-4.20%)
NVDA   131.29 (-0.29%)
NIO   15.91 (-4.90%)
BABA   84.13 (+0.02%)
AMD   67.64 (-0.38%)
T   15.91 (-1.12%)
MU   54.69 (+1.35%)
CGC   3.02 (-3.82%)
F   12.46 (+0.81%)
GE   67.59 (+0.07%)
DIS   100.11 (-1.31%)
AMC   7.39 (-5.62%)
PYPL   93.83 (+1.12%)
PFE   44.04 (-0.94%)
NFLX   233.71 (-2.92%)
NASDAQ:FENC

Fennec Pharmaceuticals - FENC Price Target & Analyst Ratings

$7.83
+0.02 (+0.26%)
(As of 10/5/2022 11:23 AM ET)
Add
Compare
Today's Range
$7.83
$7.85
50-Day Range
$6.34
$8.54
52-Week Range
$3.82
$8.75
Volume
101 shs
Average Volume
291,940 shs
Market Capitalization
$204.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.75

Fennec Pharmaceuticals Consensus Rating and Price Target (2022)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Moderate Buy
Based on 5 Analyst Ratings

Consensus Analyst Price Target

$14.75
88.38% Upside
High Prediction$19.00
Average Prediction$14.75
Low Prediction$11.00
TypeCurrent
10/5/21 to 10/5/22
1 Month Ago
9/5/21 to 9/5/22
3 Months Ago
7/7/21 to 7/7/22
1 Year Ago
10/5/20 to 10/5/21
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
4 Buy rating(s)
3 Buy rating(s)
3 Buy rating(s)
4 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$14.75$12.00$12.00$14.33
Predicted Upside88.38% Upside110.53% Upside161.72% Upside102.68% Upside
Get Fennec Pharmaceuticals Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for FENC and its competitors with MarketBeat's FREE daily newsletter.


FENC Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

FENC Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Fennec Pharmaceuticals Stock vs. The Competition

TypeFennec PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
2.80
2.68
2.49
Consensus RatingModerate BuyBuyHold
Predicted Upside88.38% Upside1,093.04% Upside29.00% Upside
News Sentiment RatingNeutral News
Positive News
Neutral News
MarketBeat
Community Rating
Outperform Votes
184
65.25%
Underperform Votes
98
34.75%
Avg. Outperform Votes
166
66.67%
Avg. Underperform Votes
83
33.33%
Avg. Outperform Votes
852
68.38%
Avg. Underperform Votes
394
31.62%

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
9/29/2022Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$10.00 ➝ $15.00+101.07%
9/26/2022Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Nierengarten
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Target$11.00 ➝ $19.00+162.07%
9/7/2022Capital One Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
N. Quibria
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$11.00+49.66%
8/8/2022Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy$14.00+99.71%
11/30/2021Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
C. Duncan
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Neutral
6/24/2021HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
R. Selvaraju
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy
(Data available from 10/5/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)












FENC Price Target - Frequently Asked Questions

What is Fennec Pharmaceuticals's consensus rating and price target?

According to the issued ratings of 5 analysts in the last year, the consensus rating for Fennec Pharmaceuticals stock is Moderate Buy based on the current 1 hold rating and 4 buy ratings for FENC. The average twelve-month price prediction for Fennec Pharmaceuticals is $14.75 with a high price target of $19.00 and a low price target of $11.00. Learn more on FENC's analyst rating history.

Do Wall Street analysts like Fennec Pharmaceuticals more than its competitors?

Analysts like Fennec Pharmaceuticals more than other Medical companies. The consensus rating for Fennec Pharmaceuticals is Moderate Buy while the average consensus rating for medical companies is Buy. Learn more on how FENC compares to other companies.

Do MarketBeat users like Fennec Pharmaceuticals more than its competitors?

MarketBeat users like Fennec Pharmaceuticals less than other Medical companies. 65.25% of MarketBeat users gave Fennec Pharmaceuticals an outperform vote while medical companies recieve an average of 66.67% outperform votes by MarketBeat users.

Does Fennec Pharmaceuticals's stock price have much upside?

According to analysts, Fennec Pharmaceuticals's stock has a predicted upside of 112.80% based on their 12-month price targets.

What analysts cover Fennec Pharmaceuticals?

Fennec Pharmaceuticals has been rated by Capital One Financial, Craig Hallum, Maxim Group, and Wedbush in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:FENC) was last updated on 10/5/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.